{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:13:38Z","timestamp":1793834018787,"version":"4.6.1"},"reference-count":16,"publisher":"Japanese Society of Internal Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,3,1]]},"DOI":"10.2169\/internalmedicine.5817-25","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T22:07:24Z","timestamp":1755122844000},"page":"698-702","source":"Crossref","is-referenced-by-count":1,"title":["Clinical and Pathophysiological Characteristics of Patients in Whom Asthma Developed during Treatment with Immune Checkpoint Inhibitors: A Retrospective Single-center Study"],"prefix":"10.2169","volume":"65","author":[{"given":"Ken","family":"Maeno","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Tajiri","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Onuki","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keima","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Fukumitsu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kanemitsu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Uemura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Ohkubo","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Oguri","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Niimi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Maeno K, Fukuda S, Oguri T, Niimi A. Nivolumab-induced asthma in a patient with non-small-cell lung cancer. Ann Oncol 28: 2891, 2017.","DOI":"10.1093\/annonc\/mdx455"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Uemura T, Fukumitsu K, Maeno K, et al. Asthma caused by durvalumab after chemoradiotherapy in two patients with non-small cell lung cancer. Respirol Case Rep 9: e0835, 2021.","DOI":"10.1002\/rcr2.835"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Deng W, Chen J, Deng XY. The occurrence of asthma in an extensive-stage small-cell lung cancer patient after combination therapy with atezolizumab and anlotinib: a case report. Front Immunol 15: 1333850, 2024.","DOI":"10.3389\/fimmu.2024.1333850"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Hamada K, Yoshimura K, Oshinomi K, et al. A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer: a case report. Medicine (Baltimore) 101: e28339, 2022.","DOI":"10.1097\/MD.0000000000028339"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Roger A, Groh M, Lorillon G, et al.; the PATIO group. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) induced by immune checkpoint inhibitors. Ann Rheum Dis 78: e82, 2019.","DOI":"10.1136\/annrheumdis-2018-213857"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Jodai T, Yoshida C, Sato R, et al. A potential mechanism of the onset of acute eosinophilic pneumonia triggered by an anti-PD-1 immune checkpoint antibody in a lung cancer patient. Immun Inflamm Dis 7: 3-6, 2019.","DOI":"10.1002\/iid3.238"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Donato AA, Krol R. Allergic bronchopulmonary aspergillosis presumably unmasked by PD-1 inhibition. BMJ Case Rep 12: e227814, 2019.","DOI":"10.1136\/bcr-2018-227814"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. McAlees JW, Lajoie S, Dienger K, et al. Differential control of CD4<sup>+<\/sup> T-cell subsets by the PD-1\/PD-L1 axis in a mouse model of allergic asthma. Eur J Immunol 45: 1019-1029, 2015.","DOI":"10.1002\/eji.201444778"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Matsumoto K, Inoue H, Nakano T, et al. B7-DC regulates asthmatic response by an IFN-\u03b3-dependent mechanism. J Immunol 172: 2530-2541, 2004.","DOI":"10.4049\/jimmunol.172.4.2530"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Helou DG, Shafiei-Jahani P, Lo R, et al. PD-1 pathway regulates ILC2 metabolism and PD-1 agonist treatment ameliorates airway hyperreactivity. Nat Commun 11: 3998, 2020.","DOI":"10.1038\/s41467-020-17813-1"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Hellings PW, Vandenberghe P, Kasran A, et al. Blockade of CTLA-4 enhances allergic sensitization and eosinophilic airway inflammation in genetically predisposed mice. Eur J Immumol 32: 585-594, 2002.","DOI":"10.1002\/1521-4141(200202)32:2<585::AID-IMMU585>3.0.CO;2-U"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Harada T, Uetani N, Inui G, et al. Pembrolizumab-induced asthma exacerbation with hypereosinophilia and elevated interleukin-5 in endometrial cancer: a case report. Respir Med Case Rep 49: 102035, 2024.","DOI":"10.1016\/j.rmcr.2024.102035"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Sumi T, Nagahisa Y, Matsuura K, et al. Successful management of severe bronchial asthma exacerbated by anti-PD-L1 treatment: a report of two cases. Respirol Case Rep 9: e0868, 2021.","DOI":"10.1002\/rcr2.868"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Bernard-Tessier A, Jeanville P, Champiat S, et al. Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies. Eur J Cancer 81: 135-137, 2017.","DOI":"10.1016\/j.ejca.2017.05.017"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Scanvion Q, B\u00e9n\u00e9 J, Gautier S, et al. Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database. Onco Immunology 9: 1722022, 2020.","DOI":"10.1080\/2162402X.2020.1722022"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Braaten TJ, Brahmer JR, Forde PM, et al. Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann Rheum Dis 79: 332-338, 2020.","DOI":"10.1136\/annrheumdis-2019-216109"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/5\/65_5817-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T03:45:54Z","timestamp":1772855154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/5\/65_5817-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5817-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]},"article-number":"5817-25"}}